Why the Clinuvel Pharmaceuticals share price is down 8% today

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has fallen over 9% today

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has fallen more than 9% during trading today. CUV shares opened at $35.57 this morning but at the time of writing, the price has dropped to $32.99, a fall of around 8.49%.

The reasons for this drop are not entirely clear, although it may involve some profit taking. At today's open price, Clinuvel shares were up 97.6% YTD, and 62% over the last three months. These price gains were likely assisted by the company's inclusion in the S&P/ASX 200 (INDEXASX: XJO) index as of 24 June.

Today's drop may also involve a delayed reaction to Clinuvel's 'communiqué', which was released to the market yesterday before opening. Clinuvel provided an update on the pending US Food and Drug Administration review of its SCENESSE (afamelanotide) product, which has been extended by three months to 6 October 2019.

Clinuvel hopes that SCENESSE (if approved) will be useful in treating erythropoietic protoporphyria (EPP), of which (according to Clinuvel) there is little effective treatment currently available to US patients, many of whom travel to Europe for treatment.

In its release, the company stated: "although the extension… for three months is not our favoured outcome, we remind all stakeholders that if insurmountable outstanding scientific issues were identified during the filing stage, and/or major deficiencies were identified during their due diligence to date, the FDA has always been able to issue a Refusal to File (RTF) and/ or recommend a withdrawal of the NDA. Since these events had not occurred, we embrace a cautious optimism and bear the patience to a long-awaited outcome."

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

An ASX shares broker analysing a chart tracking the A2 Milk share price
Share Market News

Are these two struggling ASX materials shares undervalued?

Are these buy-low candidates?

Read more »

Female miner smiling in front of a mining vehicle as the Pilbara Minerals share price rises
Broker Notes

Expert says this ASX All Ords small cap mining stock could rocket 38%

Big upside ahead?

Read more »

Happy man working on his laptop.
Share Market News

5 things to watch on the ASX 200 on Wednesday

It looks set to be another good session for Aussie investors tdaoy.

Read more »

Two laughing young women hold shopping bags and ride an escalator up to another level in a Scentre Group shopping centre.
Broker Notes

3 ASX consumer sector shares to buy in July: expert

A leading expert has named its top 3 picks.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Broker says WiseTech shares can hit $135

Bell Potter has good things to say about this rebounding tech stock.

Read more »

a man holds a firework sparkler in both hands as a shower of sparkly confetti falls from the sky around him as he smiles and closes his eyes in a celebratory scene.
Broker Notes

Stock market outlook: Macquarie 'ready to party like its 1999'

It may not be too late to invest in the share market according to the broker.

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Broker Notes

The smartest Australian stocks to buy with $400 right now

Let's see why these shares are highly rated by brokers.

Read more »

Woman and man calculating a dividend yield.
Share Market News

What ASX 200 investors just learned about the next RBA interest rate move

Will ASX 200 investors get a much-awaited interest rate cut in August?

Read more »